COMP <GO>
PRCT vs AORT // PIOTROSKI F-SCORE QUALITY
PROCEPT BioRobotics Corporation (NASDAQ) VS. Artivion Inc. (NYSE) • 15-METRIC TALLY: PRCT 4
— AORT 6
▲ PIOTROSKI F-SCORE QUALITY LEADER: AORT
LAST: $20.30 (+0.50%) • MKT CAP: $1.16B
piotroski-score
4/9
LAST: $23.44 (+2.27%) • MKT CAP: $1.14B
piotroski-score
9/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRCT VS. AORT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PRCT | AORT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 63.70% | 64.40% | -0.70 | AORT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 4.50% | -39.50 | AORT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 19.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.02% | 0.07% | -5.09 | AORT | /fcf-yield <GO> |
| Operating Margin | -33.70% | 7.60% | -41.30 | AORT | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 2.20% | -2.20 | AORT | /net-margins <GO> |
| Revenue Growth (YoY) | 37.20% | 13.60% | +23.60 | PRCT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.98 | 2.46 | +1.52 | PRCT | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 4/9 | 9/9 | -5.00 | AORT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.7 | 46.6 | +4.14 | PRCT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 98.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.16B | $1.14B | $19.8M | PRCT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PRCT REV | AORT REV | PRCT GROSS % | AORT GROSS % | PRCT FCF | AORT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $308.1M | $441.3M | 63.7% | 64.4% | -$58.3M | $839.0K |
| FY 2024 | $224.5M | $388.5M | 61.1% | 64.0% | -$103.6M | $11.0M |
| FY 2023 | $136.2M | $354.0M | — | — | -$108.0M | $18.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRCT // BETA —
AORT // BETA —